Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Purpose: Bloodstream infections (BSIs) caused by antimicrobial-resistant pathogens, especially WHO-Bacterial-Priority-Pathogens (WHO-BPPs), contribute to significant mortality. The current study determined the prevalence of BSIs, causative bacterial pathogens and their antimicrobial susceptibility profiles, and factors associated with laboratory-confirmed BSIs by WHO-BPPs during and after National Action Plan on Antimicrobial Resistance (NAP-AMR) implementation in Mwanza, Tanzania.
Patients And Methods: A comparative cross-sectional study was conducted among sepsis patients in District, Regional, and Zonal Referral Hospitals from June 2019 to June 2020 (during NAP-AMR) and March to July 2023 (after NAP-AMR). Blood cultures were processed using conventional methods, while bacterial identification and antimicrobial susceptibility testing were performed using Vitek MS (MALDI-TOF-MS) and Vitek 2, respectively. STATA version 15.0 was used for data analysis.
Results: Among 1842 enrolled patients (median age: 5 years, IQR: 0-31), 51.4% were female. The overall prevalence of BSIs was 14.7% (271/1842). A total of 306 bacterial isolates were identified, with Gram-negative bacteria predominating during (92.4%) and after (73.5%) NAP-AMR. was most common during (31.2%), whereas dominated after (43.4%) NAP-AMR. BSIs caused by WHO-BPPs rose significantly after NAP-AMR (43.5% vs 76.1%, p<0.001), particularly extended-spectrum beta-lactamase producing Enterobacterales. resistance to cefotaxime (65.3% vs 93.2%, p=0.001), gentamicin (63.3% vs 94.9%, p=0.001), and ciprofloxacin (28.6% vs 76.3%, p=0.001) increased significantly. Higher-tier hospitals (OR: 7.01; 95% CI: 1.58-31.05; p=0.010) and after NAP-AMR enrollment (OR: 2.87; 95% CI: 1.33-6.19; p=0.007) were linked to increased BSIs caused by WHO-BPPs.
Conclusion: We observed a high prevalence of BSIs with a rising proportion of BSIs caused by WHO-BPPs, particularly in higher-tier hospitals and after the implementation of NAP-AMR. Our findings highlight the need of hospital-specific antibiograms and reinforced infection prevention measures.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12404259 | PMC |
| http://dx.doi.org/10.2147/IDR.S542495 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Synergistic antimicrobial and antibiofilm effects of plant-active ingredients and antibiotics on multidrug-resistant Acinetobacter baumannii.
J Appl Microbiol
September 2025
Sivas Cumhuriyet University, Faculty of Medicine, Department of Medical Microbiology, 58140 Sivas, Türkiye.
Aims: The increasing antimicrobial resistance, particularly in Acinetobacter baumannii, complicates the treatment of infections, leading to higher morbidity, mortality, and economic costs. Herein, we aimed to determine the in vitro antimicrobial, synergistic, and antibiofilm activities of colistin (COL), meropenem, and ciprofloxacin antibiotics, and curcumin, punicalagin, geraniol (GER), and linalool (LIN) plant-active ingredients alone and in combination against 31 multidrug-resistant (MDR) A. baumannii clinical isolates.
View Article and Find Full Text PDFEffects of metformin on gut microbiota and short/mediumchain fatty acids in highfat diet rats.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
May 2025
Department of Laboratory Animal Science, Xiangya School of Medicine, Central South University, Changsha 410013, China.
Objectives: Recent evidence suggests that the gut may be a primary site of metformin action. However, studies on the effects of metformin on gut microbiota remain limited, and its impact on gut microbial metabolites such as short-/medium-chain fatty acids is unclear. This study aims to investigate the effects of metformin on gut microbiota, short-/medium-chain fatty acids, and associated metabolic benefits in high-fat diet rats.
View Article and Find Full Text PDFOvercoming Multi-Drug-Resistant Infections.
Microb Drug Resist
September 2025
Students Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Antimicrobial resistance (AMR) is one of the most important concerns in the world, occurring for both Gram-positive and Gram-negative bacteria. () is a Gram-negative bacterium belonging to the family of Enterobacteriaceae and also plays an important role in development of nosocomial infections. Three forms have emerged as a result of AMR including multi-drug resistant (MDR), extensively drug-resistant, and pan-drug-resistant.
View Article and Find Full Text PDFGenomic Characterisation of Limosilactobacillus fermentum CRL2085 Unveiling Probiotic Traits for Application in Cattle Feed.
Environ Microbiol Rep
October 2025
Reference Center for Lactobacilli (CERELA-CONICET), San Miguel de Tucumán, Argentina.
Limosilactobacillus fermentum CRL2085, isolated from feedlot cattle rations, displayed high efficiency as a probiotic when administered to animals. A comprehensive genomic analysis was performed to elucidate the genetic basis underlying its probiotic potential. Fifteen genomic islands and CRISPR-Cas elements were identified in its genome.
View Article and Find Full Text PDFClinical Implications and Patient Outcomes Associated with otic Resistance in Saudi Arabian Intensive Care Unit Facilities: A Perspective.
Curr Rev Clin Exp Pharmacol
September 2025
Department of Clinical Practice, College of Pharmacy, Jazan University, Saudi Arabia.
Introduction: Antimicrobial Resistance (AMR) poses a significant global health threat, leading to increased morbidity, mortality, and healthcare costs. Intensive Care Units (ICUs) are particularly susceptible to AMR due to frequent invasive procedures, extended hospital stays, and the selective pressure exerted by broad-spectrum antibiotics. This review aims to shed light on the current landscape of antibiotic resistance within ICUs of Saudi hospitals.
View Article and Find Full Text PDF